ELE-102

ELE-102 is a topical psychedelic-derived drug candidate being developed by Eleusis for ophthalmic indications, including glaucoma, disorders of tear production, allergic conjunctivitis, and uveitis. It is described by the company as a preclinical eye-disease therapy arising from its psychedelic chemistry platform, suggesting that it is likely designed to act locally in ocular tissues to modulate inflammatory and possibly neuroprotective pathways without producing systemic psychedelic effects. Publicly available information remains limited, with no disclosed target, structure, or detailed pharmacology, and no active interventional clinical trials registered as of the latest reports.